Medivation has licensed a portfolio of BET bromodomain inhibitors that could have better efficacy than the company's castration-resistant prostate cancer drug Xtandi enzalutamide. Medivation got the molecules from OncoFusion as the startup's founders published compelling preclinical data for inhibiting BET in CRPC.